Wave Life Sciences (WVE) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.34
- EPS estimate
- −$0.30
- EPS surprise
- −12.40%
- Revenue surprise
- −65.22%
- Revenue
- $2.3M
- Revenue estimate
- $6.5M
- Reported
- Jul 30, 2026
Wave Life Sciences reported Q2 2026 results on July 30, 2026, posting a loss of $0.34 per share. That was 12.40% wider than the $0.30 loss analysts expected and slightly wider than the $0.31 loss in Q2 2025. Revenue was $2.3 million, well below the $6.5 million estimate and down from $8.7 million a year earlier.
Losses are the norm in this record. Only two of the last 20 quarters were profitable: Q3 2023 at $0.07 per share and Q4 2024 at $0.18, which was also the highest revenue quarter in the table at $83.7 million. The annual loss narrowed from $2.13 per share in 2022 to $0.55 in 2023, then widened to $0.78 in 2024 and $1.22 in 2025. Quarterly revenue is uneven: Q1 2026 brought $38.2 million, against $2.3 million in Q2. Wave beat the EPS estimate 7 times in 20 quarters and missed in six of the last eight.
Q3 results arrived between November 9 and November 12 in each of the past five years. That points to around mid-November 2026 for the next report, which will show whether the loss per share stays near the recent $0.30 range.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | −$0.30 | −$0.34 | −12.40% | $2.3M | SEC |
| Q1 2026 | Apr 28, 2026 | −$0.32 | −$0.13 | +59.81% | $38.2M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.27 | −$0.30 | −9.57% | $17.2M | SEC |
| Q3 2025 | Nov 10, 2025 | −$0.30 | −$0.32 | −5.19% | $7.6M | SEC |
| Q2 2025 | Jul 30, 2025 | −$0.28 | −$0.31 | −11.79% | $8.7M | SEC |
| Q1 2025 | May 8, 2025 | −$0.26 | −$0.29 | −11.75% | $9.2M | SEC |
| Q4 2024 | Mar 4, 2025 | −$0.18 | $0.18 | +200.67% | $83.7M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.28 | −$0.47 | −66.20% | −$7.7M | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.21 | −$0.25 | −20.54% | $19.7M | SEC |
| Q1 2024 | May 9, 2024 | −$0.19 | −$0.24 | −29.03% | $12.5M | SEC |
| Q4 2023 | Mar 6, 2024 | −$0.23 | −$0.15 | +33.83% | $29.1M | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.18 | $0.07 | +139.26% | $49.2M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.33 | −$0.20 | +39.65% | $22.1M | SEC |
| Q1 2023 | May 3, 2023 | −$0.04 | −$0.27 | −575.00% | $12.9M | SEC |
| Q4 2022 | Mar 22, 2023 | −$0.41 | −$0.47 | −14.63% | $1.2M | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.50 | −$0.42 | +15.44% | $285,000.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.51 | −$0.62 | −21.16% | $375,000.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.54 | −$0.62 | −14.52% | $1.8M | SEC |
| Q4 2021 | Mar 3, 2022 | −$0.52 | −$0.61 | −16.66% | $1.8M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.60 | −$0.12 | +80.05% | $36.4M | SEC |
Quarterly revenue
Frequently asked questions
When did Wave Life Sciences (WVE) last report earnings?
Wave Life Sciences last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did WVE beat earnings estimates?
No. Wave Life Sciences reported EPS of −$0.34 for Q2 2026 against a −$0.30 estimate — a 12.40% miss.
How much revenue did WVE report last quarter?
Wave Life Sciences reported $2.3M in revenue for Q2 2026, against a consensus estimate of $6.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.